Balance between angiotensin converting enzyme and angiotensin converting enzyme 2 in patients with chronic heart failure. 2015

Jiang Wang, and Nan Li, and Feng Gao, and Rong Song, and Shanjun Zhu, and Zhaohua Geng
Department of Cardiology, Xinqiao Hospital, the Third Military Medical University, China.

OBJECTIVE It has been reported that angiotensin converting enzyme 2 (ACE2) is an endogenous counter-regulator of the renin-angiotensin-aldosterone system. However, angiotensin converting enzyme (ACE)/ACE2 balance in the development of human heart failure is not well established. METHODS Here we evaluated the expression of ACE and ACE2 at the mRNA and protein levels in the myocardium of 78 patients with mild or moderate to severe heart failure and in 13 cases with normal myocardium. RESULTS In the myocardium of patients with dilated or ischemic cardiomyopathy, ACE and ACE2 expression at the mRNA and protein levels was significantly increased compared with those in normal myocardium (P<0.01, P<0.01, respectively). The ratios of ACE/ACE2 mRNA and ACE/ACE2 were lower in the myocardium of patients with mild heart failure than those in normal myocardium but higher than those in patients with moderate to severe heart failure. CONCLUSIONS ACE and ACE2 expression at the mRNA and protein levels are significantly increased in the myocardium of patients with heart failure. The compensatory mechanism of patients with mild heart may cause the decreased ACE/ACE2 ratio. However, increased ACE/ACE2 ratios may induce angiotensin II over-activation and accelerate cardiac remodeling in patients with moderate to severe heart failure.

UI MeSH Term Description Entries
D007703 Peptidyl-Dipeptidase A A peptidyl-dipeptidase that catalyzes the release of a C-terminal dipeptide, oligopeptide-|-Xaa-Yaa, when Xaa is not Pro, and Yaa is neither Asp nor Glu. Thus, conversion of ANGIOTENSIN I to ANGIOTENSIN II, with increase in vasoconstrictor activity, but no action on angiotensin II. It is also able to inactivate BRADYKININ, a potent vasodilator; and has a glycosidase activity which releases GPI-anchored proteins from the membrane by cleaving the mannose linkage in the GPI moiety. (From https://www.uniprot.org April 15, 2020). ACE1 Angiotensin-Converting Enzyme 1,ACE1 Protein,Angiotensin Converting Enzyme,Angiotensin Converting Enzyme 1,Antigens, CD143,CD143 Antigens,Dipeptidyl Carboxypeptidase I,Kininase II,Peptidase P,Angiotensin I-Converting Enzyme,Carboxycathepsin,Dipeptidyl Peptidase A,Kininase A,ACE1 Angiotensin Converting Enzyme 1,Angiotensin I Converting Enzyme,Carboxypeptidase I, Dipeptidyl,Peptidyl Dipeptidase A
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D005260 Female Females
D006333 Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION. Cardiac Failure,Heart Decompensation,Congestive Heart Failure,Heart Failure, Congestive,Heart Failure, Left-Sided,Heart Failure, Right-Sided,Left-Sided Heart Failure,Myocardial Failure,Right-Sided Heart Failure,Decompensation, Heart,Heart Failure, Left Sided,Heart Failure, Right Sided,Left Sided Heart Failure,Right Sided Heart Failure
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000085962 Angiotensin-Converting Enzyme 2 A transmembrane glycoprotein with an extracellular catalytic domain which functions as a carboxypeptidase. It cleaves a single C-terminal residue from a distinct range of substrates. The catalytic efficiency is 400-fold higher with ANGIOTENSIN II as a substrate than with ANGIOTENSIN I. Angiotensin-converting enzyme 2 is also is a functional receptor for the spike glycoprotein (SPIKE PROTEIN, CORONAVIRUS) of the CORONAVIRUSES SARS-COV, SARS-COV2, and HCOV-NL63. ACE-Related Carboxypeptidase,ACE2 Angiotensin-Converting Enzyme Protein 2,ACE2 Enzyme,ACE2 Protein,Angiotensin Converting Enzyme 2,Angiotensin-Converting Enzyme-Related Carboxypeptidase,ACE Related Carboxypeptidase,ACE2 Angiotensin Converting Enzyme Protein 2,Angiotensin Converting Enzyme Related Carboxypeptidase,Carboxypeptidase, ACE-Related,Carboxypeptidase, Angiotensin-Converting Enzyme-Related
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

Jiang Wang, and Nan Li, and Feng Gao, and Rong Song, and Shanjun Zhu, and Zhaohua Geng
February 1993, The American journal of physiology,
Jiang Wang, and Nan Li, and Feng Gao, and Rong Song, and Shanjun Zhu, and Zhaohua Geng
January 2012, Drug discovery today. Therapeutic strategies,
Jiang Wang, and Nan Li, and Feng Gao, and Rong Song, and Shanjun Zhu, and Zhaohua Geng
October 1988, Deutsche medizinische Wochenschrift (1946),
Jiang Wang, and Nan Li, and Feng Gao, and Rong Song, and Shanjun Zhu, and Zhaohua Geng
November 2004, Journal of the American College of Cardiology,
Jiang Wang, and Nan Li, and Feng Gao, and Rong Song, and Shanjun Zhu, and Zhaohua Geng
August 1990, The Canadian journal of cardiology,
Jiang Wang, and Nan Li, and Feng Gao, and Rong Song, and Shanjun Zhu, and Zhaohua Geng
March 2005, Annals of internal medicine,
Jiang Wang, and Nan Li, and Feng Gao, and Rong Song, and Shanjun Zhu, and Zhaohua Geng
March 2005, Annals of internal medicine,
Jiang Wang, and Nan Li, and Feng Gao, and Rong Song, and Shanjun Zhu, and Zhaohua Geng
March 2005, Annals of internal medicine,
Jiang Wang, and Nan Li, and Feng Gao, and Rong Song, and Shanjun Zhu, and Zhaohua Geng
July 2023, Frontiers in bioscience (Landmark edition),
Jiang Wang, and Nan Li, and Feng Gao, and Rong Song, and Shanjun Zhu, and Zhaohua Geng
April 1990, Clinical and experimental pharmacology & physiology,
Copied contents to your clipboard!